about
P123
When to Start Anti-HIV Drugs in Patients With Opportunistic InfectionsA Phase I/II Study With CEA(6D) VRP Vaccine in Patients With Advanced or Metastatic CEA-Expressing MalignanciesA Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate CancerImmunotherapy Study for Surgically Resected Pancreatic CancerDinutuximab in Combination With Sargramostim in Treating Patients With Recurrent OsteosarcomaPEP-CMV in Recurrent MEdulloblastoma/Malignant GliomaOlaparib and Radium Ra 223 Dichloride in Treating Men With Metastatic Castration-Resistant Prostate Cancer That Has Spread to the BoneLung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching BiomarkersPhase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLCPhase II Trial of Allovectin-7® for Metastatic MelanomaEfficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer PatientsBasiliximab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused LymphopeniaPhase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal CancerDendreon Lymph Node Biopsy in Metastatic Castrate-Resistant Prostate CancerNivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal CancerNeoadjuvant PembrolizumabPegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerEvaluation of Tumor and Blood Immune Biomarkers in Resected Non-small Cell Lung CancerOlaparib With or Without Atezolizumab in Treating Patients With Locally Advanced or Metastatic Non-HER2-Positive Breast CancerCarboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast CancerCombination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch RepairPhase 1b Study PVSRIPO for Recurrent Malignant Glioma in ChildrenVaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma MultiformeVaccine Therapy in Treating Patients Undergoing Surgery for Recurrent Glioblastoma MultiformeVaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (ACTIVATe)Symptom Clusters in Children With LeukemiaAn Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Subjects With Acute Myeloid Leukemia (AML)An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 MutationCombination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk RhabdomyosarcomaOsimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung CancerOlaparib and Cediranib Maleate in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerSafety, Tolerability, Efficacy, and Pharmacokinetic Study of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10%Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung CancerA Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated BiomarkersMonocyte Phenotypic and Functional DifferencesDepression and Heart Failure Disease ProgressionStool Transplants to Treat Refractory Clostridium Difficile ColitisA 6-week, Study of MG01CI Low Dose and High Dose Compared With Placebo in Adults and Adolescents With Fragile X SyndromeCytomegalovirus (CMV) RNA-Pulsed Dendritic Cells for Pediatric Patients With Newly Diagnosed WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent MedulloblastomaA Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma
P6153
P750
Q42172617-45F33898-E0C6-4162-97B2-BA605D80E68BQ52344484-7D623874-AB1F-46C4-99DF-84C1317506A5Q57038308-2bff0dfe-4f69-d1f1-dd27-c92275f4b303Q58181202-2B55F873-19DF-4BB2-A73F-9B65956FE4FFQ84819221-47920A32-1606-4364-A76E-4BC83EE0D875Q85260036-995D1D86-5C49-464E-9D71-5E2944AB4C1DQ86860691-7648F795-D26A-47B0-A125-8B48A20E3F65Q87605521-FC4141D5-D5DA-400F-B9F7-9645DD9F8389Q88007963-15FBFBF2-E699-4F9B-B9AE-8005119A40D3Q88320591-16D1EC42-2CA7-48AF-923C-7610FBF534F8Q88563843-07F92B49-5FB2-4362-8C9C-EAA78C97A6A5Q89470824-5EB901F7-7F9B-417A-8303-72A435A5DC91
P108
description
healthcare organization in Durham, United States
@en
name
Duke University Medical Center
@en
type
label
Duke University Medical Center
@en
altLabel
Duke Medical Center
@en
Duke University Hospital Medical Center
@en
prefLabel
Duke University Medical Center
@en
P214
P244
P131
P1448
Duke University Medical Center
@en
P213
0000 0001 2232 0951
P214
P2427
grid.414179.e
P244
P625
Point (-78.935811 36.003478)
P6782
P7859
lccn-n81070687